At a glance
- Retatrutide produced up to 24.2% body-weight loss at 48 weeks (Phase 2)
- Tirzepatide delivered about 22.5% at the top dose over 72 weeks (SURMOUNT-1)
- 5-Amino-1MQ cut fat-cell lipogenesis by 50-70% in adipocyte studies
- The GLP-1 tier suppresses appetite; the metabolic tier does not
- Stacking two peptides that do the same job wastes money
Fat-loss peptides split into two very different tiers, and the mistake most people make is treating them as one menu. One tier reprograms appetite and metabolism at the receptor level and produces the headline numbers. The other works on fat cells and mitochondria without touching hunger. Knowing which is which saves you money and disappointment.
The GLP-1 tier: where the real numbers come from
If you have seen a peptide produce double-digit body-weight loss, it was a GLP-1 receptor agonist or a multi-agonist. These are the compounds with large randomized trials behind them, not forum anecdotes.
Retatrutide, a triple agonist that hits GLP-1, GIP, and glucagon receptors, produced up to 24.2% body-weight reduction at 48 weeks in its Phase 2 trial (Jastreboff et al., NEJM 2023). Tirzepatide, the dual GIP/GLP-1 agonist behind Mounjaro and Zepbound, delivered about 22.5% at the top dose over 72 weeks in SURMOUNT-1 (Jastreboff et al., NEJM 2022). Semaglutide sits a rung below both, which is exactly why retatrutide has the attention it does.
The mechanism is appetite. These compounds slow gastric emptying and act on brain satiety centers, so you eat less without white-knuckling it. Full protocols and titration schedules live on the retatrutide dosage chart and the tirzepatide dosage chart.
Note: GLP-1 drugs are prescription medications. The cheapest legitimate route is usually compounded telehealth, not a research vial. Compare options on our cheapest GLP-1 guide.
The metabolic tier: AOD-9604, 5-Amino-1MQ, MOTS-C
This tier does not suppress appetite. It works downstream, on how fat cells store and burn energy, and the effect sizes are smaller and mostly preclinical.
5-Amino-1MQ inhibits the enzyme NNMT. In differentiating fat cells, 30 and 60 micromolar concentrations cut lipogenesis by 50% and 70%, and obese mice dosed at 20 mg/kg lost weight progressively (Neelakantan et al., 2018). It is also the only one of the three you take orally. MOTS-C, a peptide encoded inside the mitochondria, prevented diet-induced weight gain and insulin resistance in mice by activating AMPK, the same pathway exercise triggers (Lee et al., Cell Metabolism 2015). AOD-9604, a fragment of growth hormone, showed lipolytic activity in preclinical work, but its human obesity trials did not beat placebo on weight.
See the 5-Amino-1MQ dosage chart, the MOTS-C dosage chart, and the AOD-9604 dosage chart for research protocols and reconstitution math.
Side by side
| Peptide | Tier | Mechanism | Evidence level |
|---|---|---|---|
| Retatrutide | GLP-1 | Triple agonist, appetite | Phase 2 (24.2%) |
| Tirzepatide | GLP-1 | Dual agonist, appetite | Phase 3 (22.5%) |
| 5-Amino-1MQ | Metabolic | NNMT inhibition, fat cells | Preclinical |
| MOTS-C | Metabolic | AMPK activation | Preclinical |
| AOD-9604 | Metabolic | Lipolysis | Preclinical, failed human endpoint |
Which tier is for you
Bottom line: If the goal is meaningful scale weight loss, the GLP-1 tier is the only one with trial data that matches the hype. The metabolic tier is an adjunct for body recomposition, not a replacement for it. Running MOTS-C and expecting SURMOUNT numbers is the most common disappointment in this category.
The honest stack, if you want one, is a GLP-1 for the appetite work and a single metabolic peptide for the fat-cell angle. Two GLP-1 agonists at once, or three metabolic peptides stacked, is spending without a reason.
Purity and where to source
The research vials of retatrutide, tirzepatide, AOD-9604, 5-Amino-1MQ, and MOTS-C are available from Ascension Peptides with 50% off using code ENHANCED. Before you buy anything, verify the certificate of analysis on our peptide lab test database, because GLP-1 peptides in particular are a frequent target for underfilled and mislabeled vials. If you would rather run a prescription GLP-1 through a monitored telehealth program, start with the cheapest GLP-1 options.
Caveats
GLP-1 drugs carry real gastrointestinal side effects and are prescription-only for good reason. The metabolic peptides are research compounds not approved for human use, and their human weight-loss evidence is thin to absent. None of this is a shortcut around diet and training; the trial subjects who lost the most were also in structured programs.
This article is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before making any health decision.
